


Iran

Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19)



I. Key data on HPV and HPV-related cancers



Iran has a population of 30.13 millions women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 947 women are diagnosed with cervical cancer and 370 die from the

disease. Cervical cancer ranks as the 12th most frequent cancer among women in Iran and the 9th most frequent cancer among women between 15 and 44 years of age. About 2.8% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 58.6% of invasive cervical cancers are attributed to HPVs 16 or 18.

Table 1. Crude incidence rates of HPV-related cancers

	Male	Female
Cervical cancer	-	2.5
Anal cancer	0.4	0.2
Vulva cancer	-	0.0
Vaginal cancer	-	0.1
Penile cancer	0.0	-
Pharynx (excluding nasopharynx)	0.3	0.3


Table 2. Burden of cervical cancer

	Incidence	Mortality
Annual number of new cases/deaths	947	370
Crude rate	2.5	1.0
Age-standardized rate	2.8	1.2
Cumulative risk 0-74 years (%)	0.3	0.1
Ranking of cervical cancer (all years)	12th	16th
Ranking of cervical cancer (15-44 years)	9th	12th

Table 3. Burden of cervical HPV infection Iran

	No. Tested	% (95% CI)
HPV prevalence in women with normal cytology	2017	7.4 (6.3-8.6)
HPV 16/18 prevalence:		
Normal cytology	1417	2.8 (2.1-3.8)
Low-grade cervical lesions	35	42.9 (28.0-59.1)
High-grade cervical lesions	34	67.6 (50.8-80.9)
Cervical cancer	333	58.6 (53.2-63.7)

Figure 1. Comparison of the ten most frequent HPV oncogenic types in Iran among women with and without cervical lesions



*No data available. No more types than shown were tested or were positive.

Iran

Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-04-19)



II. Complementary data on cervical cancer prevention

Table 4. Factors contributing to cervical cancer (co-factors)

Smoking prevalence (%), women	1.0
Total fertility rate (live births per women)	1.9
Hormonal contraception use (%) (pill, injectable or implant), among women	18.5
HIV prevalence (%), adults (15-49 years)	0.1 [$<0.1 - 0.2$]

Table 5. Sexual behaviour

MEN	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-
WOMEN	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-


Table 6. HPV vaccine introduction

HPV vaccination programme	No Program
Date of HPV vaccination routine immunization programme start	-
HPV vaccination target age for routine immunization	-
Full course HPV vaccination coverage for routine immunization:	
% (calendar year)	-

Table 7. Cervical screening practices and recommendations

Cervical cancer screening coverage, % (age and screening interval, reference)	49.4% (Urban women aged 18-49 ever screened, Farshbaf-Khalili 2015)
Screening ages (years)	Married
Screening interval (years) or frequency of screens	3 years after 3 consecutive annual negative tests

Figure 2. Estimated coverage of cervical cancer screening in Iran, by age and study



Contact information:

ICO HPV Information Centre
 Institut Català d'Oncologia
 Avda. Gran Via de l'Hospitalet, 199-203
 08908 L'Hospitalet de Llobregat (Barcelona, Spain)
 e-mail: info@hpvcentre.net
 internet address: www.hpvcentre.net